Literature DB >> 18585007

Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population.

Yongtang Jin1, Fengyu Zhang, Sen Yang, Yunming Kong, Fengli Xiao, Yong Hou, Xing Fan, Xuejun Zhang.   

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory skin disease associated with an HLA-Cw6 allele. Higher waist-hip ratio (WHR) and body mass index (BMI) may increase the risk of psoriasis vulgaris, but, to our knowledge, no evidence of the combined effects of HLA-Cw6 and BMI, WHR are available.
OBJECTIVES: To evaluate the combined effect of HLA-Cw6, BMI and WHR on psoriasis vaulgaris.
METHODS: The data of 466 patients and 177 controls were investigated and analyzed by a hospital-based case-control study and non-condition logistic regress model.
RESULTS: There was a graded positive association of WHR and BMI with psoriasis vulgaris. Compared with a WHR of 0.80 or less than 0.80, the odds ratio (OR) was 2.36 (p < 0.01) for WHR 0.80-0.85, and 2.74 (p < 0.01) for WHR greater than 0.85. Compared with subjects with a BMI of 20 or less than 20, the multivariate OR of psoriasis were 1.20 (p > 0.05) for a BMI of 20-25, 1.84 (p < 0.05) for a BMI of more than 25 corresponding overweight (p for trend, <0.01). We found not only the risk of psoriasis for the individual with HLA-Cw6+ was 8.33 times greater than that for individual with HLA-Cw6(-) but also the risk increased approximately 35 times in individuals with HLA-Cw6+ and a overweight as compared with one with HLA-Cw6(-) and a non-overweight, and 17-fold when the individuals with HLA-Cw6+ and a WHR of more than 0.80 were compared with individuals with HLA-Cw6(-) and a WHR of 0.80 or less than 0.80, displaying the combined effect of HLA-Cw6, BMI and WHR (all p < 001).
CONCLUSION: This study suggested that HLA-Cw6, overweight and higher waist-hip ratio are material risk factors of psoriasis vulgaris, specially the combined effects of HLA-Cw6 and BMI, WHR on psoriasis vulgaris in Chinese population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585007     DOI: 10.1016/j.jdermsci.2008.04.016

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  8 in total

Review 1.  [Comorbidities and psoriasis. Impact on clinical practice].

Authors:  S Gerdes; U Mrowietz
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

Review 2.  [The effect of obesity on disease activity of inflammatory rheumatic diseases].

Authors:  Ulf Müller-Ladner; Klaus Frommer; Thomas Karrasch; Elena Neumann; Andreas Schäffler
Journal:  Z Rheumatol       Date:  2021-03-27       Impact factor: 1.372

Review 3.  Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature.

Authors:  Rita V Patel; Michael L Shelling; Srdjan Prodanovich; Daniel G Federman; Robert S Kirsner
Journal:  J Gen Intern Med       Date:  2011-04-07       Impact factor: 5.128

4.  Incidence of psoriasis in children: a population-based study.

Authors:  Megha M Tollefson; Cynthia S Crowson; Marian T McEvoy; Hilal Maradit Kremers
Journal:  J Am Acad Dermatol       Date:  2009-12-05       Impact factor: 11.527

5.  The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years.

Authors:  Agnieszka B Owczarczyk-Saczonek; Roman Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2015-10-29       Impact factor: 1.837

Review 6.  IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.

Authors:  Esther von Stebut; Wolf-Henning Boehncke; Kamran Ghoreschi; Tommaso Gori; Ziya Kaya; Diamant Thaci; Andreas Schäffler
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

7.  HLA-Cw6 Status and Treatment Responses Between Psoriasis Patients.

Authors:  Berkay Temel; Esra Adisen; Sevim Gonen
Journal:  Indian J Dermatol       Date:  2021 Nov-Dec       Impact factor: 1.494

Review 8.  Aberrations in Lipid Expression and Metabolism in Psoriasis.

Authors:  Julia Nowowiejska; Anna Baran; Iwona Flisiak
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.